Abstract: The vaginal contraceptive sponge, approved on April 1, 1983 by the US Food Administration (FDA) for sale in the US as a single use, disposable, over-the-counter contraceptive, is made of polyurethane and designed to be biocompatible with the vaginal environment. The sponge is available in a single size, is round, and about 5.5 cm in diameter and 2.5 cm thick. An indentation on 1 side helps to ensure the sponge's correct placement against the cervix. A polyester retrieval loop attached to the sponge facilitates removal. Postcoital tests of the sponge without the spermicide indicated that it was ineffective in preventing sperm from entering the cervical canal. Before insertion, the contraceptive sponge is moistened with tap water to activate the spermicide and is inserted into the vagina with the indentation placed against the cervis. The sponge has been designed to provide continuous protection against pregnancy for at least 24 hours after insertion. Following a successful phase ii clinical trail of the sponge, in 1979 comparative phase iii clinical trials were initiated by Family Health International. The following trials were conducted: sponge versus the diaphragm (arcing-spring) used with a spermicide (nonoxynol-9) at 13 clinics in the US (1439 subjects) and at 2 clinics in Canada and the UK (502 subjects); sponge versus a foaming spermicidal (menfegol) suppository at 5 clinics in Yugoslavia, Taiwan, and Bangladesh (1386) subjects); and sponge versus spermicidal (nonoxynol-9) foam at 2 clinics in Israel and Thailand (366 subjects). In all trials the contraceptive methods were raondomly assigned. Clinics were required to follow up subjects for 1 year. Only the US study has been completed. In the comparative trials of the sponge and diaphragm (both US based and overseas) the pregnancy rates were significantly higher for the sponge. In the comparative trials of the sponge and foaming suppositories or spermicidal foam there were no significant differences between the pregnancy rates of the sponge and the other contraceptive methods. In the US based trial of the sponge the differences between cumulative 12 month pregnancy rates were relatively small--16.8 and 12.5 pregnancies/100 women for sponge and diaphragm users, respectively. No cases of toxic shock syndrime (TSS) or other serious omplications have occurred among 1848 women who have participated in the clinical trials of the sponge and who have accounted for 1068 woman years of sponge use. Advantages of the sponge include: it can be purchased without prescription and is easy to use and is not messy; sexual spontaneity is enhanced in that it may be inserted up to 24 hours before sexual intercourse; a single size fits all women; and after insertion, it immediately provides protection against pregnancy for at least 24 hours.

Regulation of the Processing of Glucose-6-phosphate Dehydrogenase mRNA by Nutritional Status*

Recent findings in the regulation of G6PD and its role in diseases

In Vivo Phosphorylation of the Cytosolic Glucose-6-Phosphate Dehydrogenase Isozyme G6PD6 in Phosphate-Resupplied Arabidopsis thaliana Suspension Cells and Seedlings

Lomotil in acute diarrhoea.

O-GlcNAcylation of G6PD Promotes the Pentose Phosphate Pathway and Tumor Growth

Resistance of the embryonic notochord to invasion by malignant neurogenic tumor cellsin vitro

Glucose-6-phosphate dehydrogenase exerts antistress effects independently of its enzymatic activity

A small molecule G6PD inhibitor reveals immune dependence on pentose phosphate pathway

The vaginal contraceptive sponge.

Regulation of G6PD Acetylation by SIRT2 and KAT9 Modulates NADPH Homeostasis and Cell Survival During Oxidative Stress

Modeling human glucose-6-phosphate dehydrogenase mutations using C. elegans GSPD-1

Functional effects of an African glucose‐6‐phosphate dehydrogenase (G6PD) polymorphism (Val68Met) on red blood cell hemolytic propensity and post‐transfusion recovery

Abstract 5177: SIRT2 Deacetylates and Activates Glucose-6-phosphate Dehydrogenase (G6PD) to Protect Cells Against Oxidative Stress.

Glucose 6-phosphate dehydrogenase is regulated through c-Src-mediated tyrosine phosphorylation in endothelial cells

Exposure to 6-PPD quinone enhances glycogen accumulation in Caenorhabditiselegans

Alternative splicing of Arabidopsis G6PD5 recruits NADPH-producing OPPP reactions to the endoplasmic reticulum

Limited form of Wegener granulomatosis. Eye involvement as a major sign.

Increased exercise tolerance in humanized G6PD deficient mice

Control of Blood Glucose in the Absence of Hepatic Glucose Production During Prolonged Fasting in Mice

Functional Analysis of G6PD Variants Associated With Low G6PD Activity in the All of Us Research Program

G6pd-Deficient Mice Are Protected From Experimental Cerebral Malaria and Liver Injury by Suppressing Proinflammatory Response in the Early Stage of Plasmodium berghei Infection